Publication: Unraveling trastuzumab emtansine resistance in HER2-positive advanced breast cancer: GEICAM KATIA study
Authors
Rojo Todo, F. ; Stradella, A. ; García Sáenz, J. A. ; Bermejo de las Heras, B. ; Alonso Romero, José Luis ; Barnadas, A. ; Izarzugaza Peron, Y. ; Alba, E. ; López Tarruella, S. ; Henao Carrasco, F. ; Carrasco, E. ; Caballero, R. ; Del Campo, M.
item.page.secondaryauthor
item.page.director
Publisher
Elsevier
publication.page.editor
publication.page.department
DOI
https://doi.org/10.1016/j.annonc.2020.08.456
item.page.type
info:eu-repo/semantics/article
Description
© 2020 European Society for Medical Oncology. This document is the Published version of a Published Work that appeared in final form in Annals of Oncology. To access the final edited and published work see https://doi.org/10.1016/j.annonc.2020.08.456
Abstract
T-DM1 is the standard second-line treatment for HER2-positive Metastatic Breast Cancer (HER2+ MBC) patients. In clinical practice, it is not possible to predict which patients will benefit the most from T-DM1. Furthermore, the mechanisms of primary and acquired resistance to T-DM1 remain largely uncharacterized. The task of uncovering such mechanisms in a clinical setting is challenging and requires a comprehensive approach.
publication.page.subject
Citation
Annals of Oncology, 2020, Vol. 31, Issued S4, pp. S391
item.page.embargo
1-ene-2999
Collections
Ir a Estadísticas
Sin licencia Creative Commons.